Acute electric field downregulates human plasma immunoreactive interleukin-6 and -1β levels: Molecular mechanisms underlying inflammation alleviation through electric field therapy

Yuzo Nakagawa-Yagi1*, Hiroyuki Hara1, Chisato Kanaı̂1, Masashi Sato1 and Akikuni Hara1

1Hakuju Institute for Health Science Co. Ltd., 37-5 Tomigaya 1-chome, Shibuya-ku, Tokyo 151-0063, Japan
2Kyoto Constella Technologies Co. Ltd., Kyozome Kaikan, 481 Tourouyama-cho, Nakagyo-ku, Kyoto 604-8225, Japan
3Acel, Inc., SIC-2 2506, 5-4-30 Nishihashimoto, Midori-ku, Sagamihara, Kanagawa 252-0131, Japan

Abstract

Medical treatment using high-voltage electric potential (HELP) devices to generate an electric field (EF) is an alternative therapy commonly used in Japan. However, the mechanisms underlying potential health benefits of this therapy are still unclear. Therefore, we investigated the effect of HELP exposure (9 kV/electrode+9 kV electrode, 30 min) on several cytokines and hormones using enzyme-linked immunosorbent assays in plasma samples obtained from healthy human subjects before and after a single treatment session. Immunoreactive interleukin (IL)-1β and IL-6 levels were significantly downregulated following HELP exposure. Under these treatment conditions, HELP exposure did not exert on immunoreactive IL-10, IL-18, transforming growth factor-beta 1 (TGF-β1), tumor necrosis factor-alpha (TNF-α) adrenaline, serotonin, histamine, neuropeptide Y, somatostatin, insulin, or dehydroepiandrosterone sulfate (DHEAS) levels. The activation of transient receptor potential melastatin 8 (TRPM8) induces the suppression of the levels of inflammatory markers. Therefore, we further examined the in silico docking simulation of lysoPC-22:4, lysoPE-20:4, and lysoPE-22:6 with TRPM8 using a homology model. The binding energies were -10.8, -10.4, and -11.4 kcal/mol for lysoPC-22:4, lysoPE-20:4, and lysoPE-22:6, respectively. Our findings provide new insights into the molecular mechanisms underlying pain control and sleep quality alleviation following EF therapy.


Introduction

A therapeutic device exposing the human body to high-voltage electric potential (HELP) has been approved by the Ministry of Health, Labour and Welfare in Japan [1-19]. High-voltage electric field (EF) therapy is reported to be an effective treatment for shoulder stiffness, headache, insomnia, and chronic constipation [1-20]. Although EF therapy was discovered more than 80 years ago, the molecular mechanisms associated with its health benefits remain elusive. Altogether, the results of these studies suggest that HELP exposure may be an alternative therapy for several conditions. Our previous attempts to identify biomarker induced by HELP exposure using plasma metabolomics and lipidomics have led to the detection of lipid-derived signaling molecules such as 3-hydroxybutyrate (3-HBA), cis-8,11,14-eicosatrienoic acid, 9-hydroxyoctadecadienoic acid (9-HODE), 13-hydroxyoctadecadienoic acid (13-HODE), oleoyl ethanolamide (OEA), lysophosphatidylethanolamine (lysoPE)-20:4, and lysoPE-22:6 [21-25]. Endogenous lipid-derived signaling molecules have been suggested as candidate molecules, representing the interface between symptoms and electroceutical target proteins [21-26]. A recent study conducted by Smani et al. reported that pretreatment with lysophosphatidylcholine (lysoPC) induced decreases in the levels of pro-inflammatory cytokines in the murine model of peritoneal sepsis caused by Acinetobacter baumanii [27]. In our previous study, we observed HELP exposure-induced upregulation of lysoPC-22:4 levels in the plasma of healthy individuals [28]. Therefore, we hypothesized that the increased plasma lysoPC-22:4 levels following EF exposure may be linked to changes in pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α). In
the present study, we report that the immunoreactive levels of IL-1β and IL-6 may be downregulated by HELP treatment (9 kV/electrode+9 kV/electrode, 30 min). In addition, we conducted a binding study to explore the interactions between lysoPC-22:4 and a homology model of transient receptor potential melastatin 8 (TRPM8) using the template structure (PDB ID 6BPQ).

Materials and methods

EF exposure

The system used for the EF exposure has been previously described [1-25,28]. The EF system was equipped with a transformer, a seat, and two insulator-covered electrodes. One electrode was placed on a floor plate on which the subject's feet were located, and the other electrode was placed above the subject's head. An EF generated by the HELP apparatus (Healthtron PRO-18T; Hakuju Institute for Health Science Co., Ltd., Tokyo, Japan) was uniformly created by transforming a 50-Hz alternating current at 9 kV/electrode+9 kV/electrode. The safety of this system for human use was confirmed by the Japanese government in 1963.

Subjects

Sixteen healthy adults (7 males and 9 females; mean age, 44.1 ± 1.7 years; body mass index [BMI], 22.5 ± 1.3 kg/m²) participated in experiment 1 (exposure condition: 9 kV/electrode+9 kV/electrode, 30 min). Twenty-five healthy adults (9 males and 16 females; mean age, 46.1 ± 1.1 years; BMI, 22.2 ± 0.5 kg/m²) participated in experiment 2 (exposure condition: 9 kV/electrode+9 kV/electrode, 30 min). All experiments were performed in the morning, and all participants signed an informed consent form after receiving verbal and written information regarding the study. All experiments were conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the human ethics committee of Hakuju Institute for Health Science Co., Ltd. (Tokyo, Japan).

Plasma preparation

Blood samples were collected using vacutainer tubes coated with ethylenediaminetetraacetic acid (VP-NA070K; Terumo Corporation, Tokyo, Japan) and immediately centrifuged at 800 x g for 5 min to separate the plasma from other cellular materials. The plasma was subsequently transferred to a fresh Eppendorf tube and stored at -80°C until processing.

Enzyme-linked immunosorbent assay (ELISA)

The plasma immunoreactive levels of IL-1β, IL-6, IL-10, IL-18, TGFB-β1, TNF-α, adrenaline, dehydroepiandrosterone sulfate (DHEAS), histamine, insulin, neuropeptide Y, serotonin, or somatostatin were measured using a human IL-1β, IL-6, IL-10, IL-18, TGF-β1, TNF-α ELISA kit (R&D systems, Minneapolis, MN, USA), a human IL-18 ELISA kit (Medical & Biological Laboratories, Nagoya, Japan), a human adrenaline and DHEAS ELISA kit (Lifespan Biosciences, Seattle, WA, USA), a human histamine ELISA kit (Bertin Pharma, Montigny le Bretonneux, France), a human insulin ELISA kit (Mercodia, Uppsala, Sweden), a human neuropeptide Y ELISA kit (Cloud-Clone, Houston, TX, USA), a human serotonin ELISA kit (Enzo Life Sciences, Farmingdale, NY, USA), or a human somatostatin ELISA kit (RayBiotech, Norcross, GA, USA).

Homology modeling and docking simulation

We used Q722W7.fasta registered in UniProt to obtain the sequence of human TRPM8 (hTRPM8). The three-dimensional structure (6BPQ; Protein Data Bank Japan) was used as a template structure. The best docking score was chosen from the docking calculation between icilin (an agonist of TRPM8) and a homology model. The docking study of lysoPC-22:4 binding to the target protein of the hTRPM8 model structure was performed using the AutoDock Vina docking software (Dr. Oleg Trot, The Scripps Research Institute, CA, USA) [29]. The docking experiment was performed five times and yielded 100 candidate conformations.

Statistical analysis

Data were analyzed using Welch’s t-test. A probability (p) value < 0.05 was considered statistically significant.

Results

Effect of HELP exposure on immunoreactive cytokines in the plasma of healthy individuals

We examined the effect of HELP exposure (9 kV/electrode+9 kV/ electrode) for 30 min on immunoreactive cytokines in the plasma of healthy individuals at multiple time points (Figure 1). The levels of immunoreactive IL-1β were significantly downregulated at the 0 time and 30-min time point after HELP exposure compared with those observed before the exposure (IL-1β-After 0time: 0.66-fold, p=0.00005; IL-1β-After 30-min: 0.83-fold, p=0.025). Moreover, the levels of immunoreactive IL-6 were significantly downregulated at the 30-min time point after HELP exposure compared with those observed before the exposure (IL-6: 0.68-fold, p=0.039). Under these conditions, HELP exposure did not affect the levels of immunoreactive IL-10, IL-18, TNF-α, or TGF-β1 (Figure 1c-f).

Effect of HELP exposure on immunoreactive hormones in the plasma of healthy individuals

We examined the effect of HELP exposure (9 kV/electrode+9 kV/ electrode) for 30 min on immunoreactive hormones in the plasma of healthy individuals to determine the specificity (Table 1). HELP exposure did not affect the levels of immunoreactive adrenaline, DHEAS, histamine, insulin, neuropeptide Y, serotonin, or somatostatin.


Acute EF exposure induces a notable increase in the levels of lysoPC-22:4 in the plasma of healthy subjects [28]. LysoPC-16:0 activates TRPM8 in CHO cells expressing TRPM8 [30]. Therefore, we examined the in silico docking of lysoPC-22:4 in the active site of TRPM8 using the AutoDock Vina software. We set the number of outputs poses to 20, with a total of 100 candidate conformations. LysoPC-22:4 showed good binding energy (-10.8 kcal/mol) (Table 2). LysoPC-22:4 formed hydrogen bonds with Tyr-745, Gln-782, and Tyr-1005 (Figure 1a). The results indicate that lysoPC-22:4 binds to the TRPM8 channel. Under these conditions, icilin (a well-known TRPM8 agonist) showed a strong interaction energy of -11.4 kcal/mol (Figure 1b, Table 2). In addition, we examined the in silico docking of lysoPE-20:4 and lysoPE-22:6 to the active site of TRPM8. A similar docking score was obtained using lysoPE-20:4 instead of lysoPC-22:4 (Table 2). LysoPE-22:6 showed a strong interaction energy of -11.4 kcal/mol (Table 2). LysoPE-20:4 interacted with Glu-782, Asn-799, Asp-802, Arg-842, and Tyr-1005, and lysoPE-22:6 interacted with Asn-799 and Arg-842 (Figures 1c and 1d, Table 2). Subsequently, we examined the in silico docking of 13-HODE, 9-HODE, and OEA to the active site of TRPM8 to determine...
Nakagawa-Yagi Y (2018) Acute electric field downregulates human plasma immunoreactive interleukin-6 and -1β levels: Molecular mechanisms underlying inflammation alleviation through electric field therapy

Figure 1. Effect of HELP exposure on immunoreactive cytokine levels in the plasma of healthy individuals

Effect of HELP exposure (9 kV/electrode + 9 kV/electrode, 30 min) exposure on the plasma levels of immunoreactive IL-1β (a), IL-6 (b), IL-10 (c), IL-18 (d), TNF-α (e), and TGF-β1 (f) at multiple time points. *p<0.05 compared with before exposure. **p<0.01 compared with before exposure.

Figure 2. In silico molecular docking of lysoPC-22:4, icilin, lysoPE-20:4, and lysoPE-22:6 in the TRPM8 active site


Table 1. Effect of HELP exposure (9 kV/electrode + 9 kV/electrode, 30 min) on immunoreactive hormone levels in the plasma of healthy individuals

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Before Mean ± SE</th>
<th>After Mean ± SE</th>
<th>Ratio After/Before</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenaline (ng/mL)</td>
<td>16</td>
<td>20.9 ± 0.9</td>
<td>20.5 ± 0.9</td>
<td>0.98</td>
<td>0.242</td>
</tr>
<tr>
<td>DHEAS (ng/mL)</td>
<td>16</td>
<td>144 ± 27</td>
<td>139 ± 20</td>
<td>0.97</td>
<td>0.670</td>
</tr>
<tr>
<td>Histamine (nM)</td>
<td>25</td>
<td>1.16 ± 0.37</td>
<td>1.26 ± 0.38</td>
<td>1.09</td>
<td>0.500</td>
</tr>
<tr>
<td>Insulin (mU/L)</td>
<td>16</td>
<td>12.2 ± 2.6</td>
<td>10.5 ± 2.0</td>
<td>0.86</td>
<td>0.452</td>
</tr>
<tr>
<td>Neuropeptide Y (pg/mL)</td>
<td>25</td>
<td>124 ± 5</td>
<td>117 ± 6</td>
<td>0.94</td>
<td>0.170</td>
</tr>
<tr>
<td>Serotonin (µ/mL)</td>
<td>25</td>
<td>1.09 ± 0.08</td>
<td>1.19 ± 0.09</td>
<td>1.09</td>
<td>0.313</td>
</tr>
<tr>
<td>Somatostatin (ng/mL)</td>
<td>25</td>
<td>52.1 ± 3.5</td>
<td>49.2 ± 3.2</td>
<td>0.94</td>
<td>0.481</td>
</tr>
</tbody>
</table>

doi: 10.15761/IMM.1000333

Volume 5(3): 3-6
Nakagawa-Yagi Y (2018) Acute electric field downregulates human plasma immunoreactive interleukin-6 and -1β levels: Molecular mechanisms underlying inflammation alleviation through electric field therapy

Table 2. Docking score and key interacting residues of TRPM8

<table>
<thead>
<tr>
<th>Ligand</th>
<th>Docking score (kcal/mol)</th>
<th>Interactive residues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Icilin</td>
<td>11.4</td>
<td>Tyr-745, Arg-842, and Arg-1008</td>
</tr>
<tr>
<td>LysoPC-22:4</td>
<td>10.8</td>
<td>Tyr-745, Glu-782, and Tyr-1005</td>
</tr>
<tr>
<td>LysoPE-20:4</td>
<td>10.4</td>
<td>Glu-782, Asn-799, Asp-802, Arg-842, and Tyr-1005</td>
</tr>
<tr>
<td>LysoPE-22:6</td>
<td>11.4</td>
<td>Asn-799, and Arg-842</td>
</tr>
<tr>
<td>13-HODE</td>
<td>9.1</td>
<td>Asp-802</td>
</tr>
<tr>
<td>9-HODE</td>
<td>9.3</td>
<td></td>
</tr>
<tr>
<td>OEA</td>
<td>9.8</td>
<td>Asp-781</td>
</tr>
</tbody>
</table>

the specificity. The binding energies were -9.1, -9.3, and -9.8 kcal/mol for 13-HODE, 9-HODE, and OEA, respectively (Table 2).

Discussion

In this study, we showed that the levels of IL-1β and IL-6 are sensitive to acute EF exposure in healthy humans. Notably, the absence of a pro-inflammatory cytokine TNF-α response indicates that the IL-1β and IL-6 responses are not adverse nonspecific actions of the immune function in humans. Our previous studies have shown that the IL-6 levels in the plasma of healthy individuals are ineffective after 15 min of acute EF exposure [22]. An acute EF exposure of 30 min may be necessary to develop a significant inhibitory effect on the IL-6 levels in the plasma. Further studies are warranted to identify the optimal condition for the downregulation of pro-inflammatory cytokines such as IL-6 and IL-1β induced by EF exposure. The molecular mechanisms of changes in the plasma levels of IL-6 and IL-1β following HELP exposure are complex and may be interpreted in several ways. The endogenous lipid-derived metabolite 3-hydroxybutyrate (3-HBA) has been suggested to function as an endogenous inhibitor of the NLRP3 inflammasome [31]. Using nontargeted human metabolomics, we recently demonstrated that the increase in plasma 3-HBA levels is elicited by EF exposure [24]. Interestingly, Youn et al. reported that 3-HBA inhibits the secretion of IL-1β in LPS-stimulated human monocytes without significantly affecting the production of TNF-α [32]. In addition, there is evidence that IL-6 is a known downstream target of IL-1β, consistently increased in the blood of patients with NLRP3 inflammasome-mediated conditions [33]. Thus, it is reasonable to speculate that EF exposure may inhibit the NLRP3 inflammasome through the upregulation of 3-HBA.

Furthermore, we previously showed an acute EF exposure (9 kV/electrode-9 kV/electrode, 30 min)-induced increase in the levels of lysoPC-22:4 (approximately 1.47-fold) in other lipid-derived signaling molecules [28]. Considering the role of the TRP channel family in lysoPC-22:4 (approximately 1.47-fold) in other lipid-derived signaling pathways such as IL-6 and IL-1β induced by EF exposure. The molecular mechanisms of changes in the plasma levels of IL-6 and IL-1β following HELP exposure are complex and may be interpreted in several ways. The endogenous lipid-derived metabolite 3-hydroxybutyrate (3-HBA) has been suggested to function as an endogenous inhibitor of the NLRP3 inflammasome [31]. Using nontargeted human metabolomics, we recently demonstrated that the increase in plasma 3-HBA levels is elicited by EF exposure [24]. Interestingly, Youn et al. reported that 3-HBA inhibits the secretion of IL-1β in LPS-stimulated human monocytes without significantly affecting the production of TNF-α [32]. In addition, there is evidence that IL-6 is a known downstream target of IL-1β, consistently increased in the blood of patients with NLRP3 inflammasome-mediated conditions [33]. Thus, it is reasonable to speculate that EF exposure may inhibit the NLRP3 inflammasome through the upregulation of 3-HBA.

Considerable evidence for the modulation of cytokines has been obtained from animal models of arthritis and neuropathic pain [39-42]. In particular, Naito et al. reported that static EF exposure inhibits the increased expression of IL1β, but not of TNFα in arthritic hind paws [40]. Interestingly, the sensitivity of cytokines in that study was comparable to that observed in the present study. On the other hand, Khalil et al. reported that TRPM8 in macrophages modulates colitis through a balance-shift in the production of pro-inflammatory and anti-inflammatory cytokines [43]. Moreover, Ramachandran et al. reported that activation of TRPM8 by icilin attenuates trinitrobenzenesulfonic acid- or dextran sodium sulfate-induced colonic inflammation in vivo models [44]. Thus, it is reasonable to speculate that EF exposure may alleviate inflammation through the binding of TRPM8 by lysoPC-22:4, lysoPE-20:4, and lysoPE-22:6. However, it is unclear whether changes in the levels of IL-1β and IL-6 may be attributed to neurons, macrophages, melanocytes, or keratinocytes. Although the underlying mechanisms of anti-inflammation by EF exposure remain to be elucidated, the role of lysoPC-22:4, lysoPE-20:4, or lysoPE-22:6 as endogenous agonist of TRPM8 may be potential mechanisms. Thus, it is conceivable that the decrease in IL-1β and IL-6 levels is, at least in part, responsible for the improvement observed in leprosy patients with neuroinflammation undergoing EF exposure [2-3]. Moreover, Proudfoot et al. reported that activation of TRPM8 elicits analgesia in chronic neuropathic pain models [45]. There is also evidence that activation of TRPM8 exerts an analgesic effect on acute and inflammatory pain [46]. Interestingly, Vanmolkot and de Hoon reported increased blood C-reactive protein (CRP) levels in young adult patients with migraine [47]. Using lipidomic analysis of serum samples, Ren et al. recently reported that the levels of lysoPE-22:6 are decreased in migraine patients [48]. Thus, it is reasonable to speculate that EF exposure alleviates headache such as migraine via upregulation of lysoPE-22:6. It may be interesting to evaluate the possible effect of EF exposure on migraine in future studies.

Chronic inflammation in aging has also been proposed as a strong risk factor for morbidity and mortality in elderly individuals [49]. Of note, centenarians cope with chronic subclinical inflammation through an anti-inflammatory response termed “anti-inflammaging” [50]. It
may be interesting to evaluate the possible effect of repetitive HELP exposure on human longevity in future studies.

Considerable evidence regarding an association between IL-6 and sleep quality has been obtained from studies involving aging females and a meta-analysis of cohort studies [51-53]. Interestingly, Irwin et al. reported that sleep disturbance is associated with high levels of CRP and IL-6, but not TNF-α [54]. In contrast, Milrad et al. reported that poor sleep quality is associated with greater circulating levels of TNF-α, IL-1β, and IL-6 [55]. In the present study, repeated EF treatment was not performed. Therefore, it is reasonable to speculate that EF therapy alleviates insomnia, at least in part, through the downregulation of IL-1β and IL-6 [6,15,16,20]. Further basic research studies are warranted to elucidate the alleviative effect of endogenous lipid-derived signaling molecules such as lysoPC-22:4, lysoPE-20:4, or lysoPE-22:6 on sleep disturbance.

In conclusion, acute HELP exposure induced marked inhibitory effects on the plasma levels of IL-1β and IL-6 in healthy individuals. In silico molecular docking of lysoPC-22:4, lysoPE-20:4, and lysoPE-22:6 was observed for TRPM8. Our findings provide insight into the molecular mechanisms involved in the alleviation of headache and insomnia induced by the HELP device. These mechanisms may also be important for defense against inflammaging.

Competing interests

YN-Y, HH, and AH are employed by Hakuju Institute for Health Science Co., Ltd.; CK is employed by Kyoto Contella Technologies Co., Ltd.; and MS is employed by Acel Inc. The remaining authors have no competing interests.

Authors’ contributions

YN-Y designed and supervised the research and wrote the manuscript. YN-Y, HH, AH, and MS performed EF exposure and ELISA experiments. CK performed molecular modeling. All authors have read and approved the final version of the manuscript.

Acknowledgment

We thank Dr. Makoto Kituchi (Professor Emeritus, National Defense Medical College, Japan) for encouragement. We thank Katherine Nixon who provided medical writing services on behalf of Enago Crimson Interactive Pvt. Ltd.

References

Nakagawa-Yagi Y (2018) Acute electric field downregulates human plasma immunoreactive interleukin-6 and -1β levels: Molecular mechanisms underlying inflammation alleviation through electric field therapy


35. Ahern GP (2003) Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 278: 30429-30434. [Crossref]


49. Vannella V, de Hoon JN (2007) Increased C-reactive protein in young adult patients with migraine. Cephalalgia 27: 843-846. [Crossref]


Copyright: ©2018 Nakagawa-Yagi Y. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.